LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

89.66 -0.94

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

87.87

Máximo

91.98

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+50.89% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	151M 6B
Apertura anterior	90.6
Cierre anterior	89.66

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 may 2026, 16:49 UTC

Ganancias

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 may 2026, 16:26 UTC

Principales Movimientos del Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 may 2026, 23:51 UTC

Charlas de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 may 2026, 22:33 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164M

21 may 2026, 21:53 UTC

Ganancias

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 may 2026, 21:02 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 may 2026, 20:55 UTC

Ganancias

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 may 2026, 20:30 UTC

Acciones populares

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 may 2026, 20:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 may 2026, 20:20 UTC

Charlas de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Adj EPS 3c >BULL

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Rev $159.9M >BULL

21 may 2026, 20:18 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 may 2026, 20:18 UTC

Ganancias

Webull 1Q Loss/Shr 4c

21 may 2026, 19:43 UTC

Charlas de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 may 2026, 18:58 UTC

Ganancias

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 may 2026, 18:15 UTC

Charlas de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 may 2026, 17:40 UTC

Charlas de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 may 2026, 17:04 UTC

Charlas de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 may 2026, 17:01 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Stellantis Targets Distant but Constructive -- Market Talk

21 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

50.89% repunte

Estimación a 12 Meses

Media 136.77 USD 50.89%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.